Cargando…
1例3次挑战培美曲塞方案治疗晚期非小细胞肺癌有效的个案报道
Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer, with a 5-year survival rate of less than 15%-19%, and more than 80% of the patients with lung cancer have progressed to advanced stage (Stage Ⅲb-Ⅳ) when they are clearly diagnosed. The comprehensive treatment mainly based on c...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580086/ https://www.ncbi.nlm.nih.gov/pubmed/31196375 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.11 |
Ejemplares similares
-
培美曲塞/顺铂二线治疗晚期非小细胞肺癌:一例报告及文献复习
Publicado: (2010) -
经Ommaya囊脑室内注射培美曲塞治疗非小细胞肺癌软脑膜转移1例及文献回顾
Publicado: (2019) -
2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道
Publicado: (2022) -
培美曲塞单药或联合铂类三线及以上治疗晚期非鳞型非小细胞肺癌的临床观察
Publicado: (2012) -
NP方案治疗1例肺低分化癌伴肉瘤样改变病例报道
Publicado: (2011)